Permax

(Pergolide)

Phase 3Small molecule

VValeant Pharmaceuticals

Permax is one of 174 small molecule programs targeting Cocaine Abuse. It is currently in Phase 3.

Indications

Total Trials

Active Trials

173

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cocaine AbuseActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Cocaine DependenceActive, not recruiting

Substance AbuseActive, not recruiting

Tourette SyndromeActive, not recruiting

SchizophreniaActive, not recruiting

Schizotypal Personality DisorderActive, not recruiting

Cocaine AbusePhase 2

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Cocaine DependencePhase 3

Active, not recruiting

Substance AbusePhase 2

Active, not recruiting

Tourette SyndromePreclinical

Active, not recruiting

SchizophreniaPreclinical

Active, not recruiting

Schizotypal Personality DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Permax

VValeant Pharmaceuticals

Phase 3

1 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 5

Ibrance

Pfizer

Preclinical

—6

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Compazine

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Inversine

TTargacept Inc.

Preclinical

1 9

Orap

Teva

Preclinical

2 10

Antidepressant

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unknown status·—·N/A·NCT00252044

Cognitive impairment1 trial

Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

Suspended·HHamamatsu University··NCT00197483·20 enrolled

3 more indications

Schizophrenia1 trial

Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

Completed·HHeidelberg University·N/A·NCT01066403·28 enrolled

Tourette syndrome1 trial

Randomized Study of Pergolide in Children With Tourette Syndrome

Completed·—·N/A·NCT00004433·74 enrolled

Parkinson's Disease1 trial

Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

No longer available·BBausch Health Americas, Inc.··NCT00624741

Regulatory

FDA Approval Timeline[4]

Dec 30, 1988

PERMAX

NDA NDA019385

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Pergolide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pergolide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pergolide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA019385). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Valeant Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VValeant Pharmaceuticals

Permax

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cocaine Dependence1 trial

Substance Abuse1 trial

Cocaine Abuse1 trial

Schizotypal Personality Disorder1 trial

Cognitive impairment1 trial

Schizophrenia1 trial

Tourette syndrome1 trial

Parkinson's Disease1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News